InflaRx (IFRX) News Today $1.09 -0.06 (-5.13%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period InflaRx (NASDAQ:IFRX) Given New $10.00 Price Target at GuggenheimMarch 28 at 2:53 AM | americanbankingnews.comInflaRx price target raised to $10 from $7 at GuggenheimMarch 27, 2025 | markets.businessinsider.comGuggenheim Raises InflaRx (NASDAQ:IFRX) Price Target to $10.00Guggenheim lifted their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday.March 27, 2025 | marketbeat.comInflaRx's (IFRX) "Buy" Rating Reiterated at HC WainwrightMarch 24, 2025 | americanbankingnews.comLifeSci Capital Remains a Hold on InflaRx (IFRX)March 22, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research report on Friday.March 22, 2025 | marketbeat.comInflaRx N.V. Receives European Commission Approval for GOHIBIC® (vilobelimab) and Achieves Key Development Milestones in Clinical TrialsMarch 22, 2025 | nasdaq.comInflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last yearMarch 21, 2025 | markets.businessinsider.comInflaRx (NASDAQ:IFRX) Posts Quarterly Earnings ResultsInflaRx (NASDAQ:IFRX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.March 21, 2025 | marketbeat.comPromising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market PotentialMarch 21, 2025 | tipranks.comInflaRx N.V. Reports 2024 Results and Key AchievementsMarch 21, 2025 | tipranks.comInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected MilestonesMarch 20, 2025 | markets.businessinsider.comInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected MilestonesMarch 20, 2025 | globenewswire.comShort Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2%InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 564,700 shares, a growth of 46.2% from the February 13th total of 386,300 shares. Based on an average trading volume of 382,600 shares, the short-interest ratio is currently 1.5 days. Approximately 1.0% of the shares of the company are sold short.March 16, 2025 | marketbeat.comInflaRx (IFRX) Projected to Post Earnings on ThursdayInflaRx (NASDAQ:IFRX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of InflaRx in a research note on Friday.March 8, 2025 | marketbeat.comInflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | finance.yahoo.comInflaRx announces presentation of multiple posters on utility of vilobelimabMarch 7, 2025 | markets.businessinsider.comInflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | gurufocus.comInflaRx’s Gohibic Gains Momentum with Promising Clinical Data and Regulatory Support, Backing Buy RatingMarch 7, 2025 | tipranks.comInflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | globenewswire.comInflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual MeetingFebruary 28, 2025 | finance.yahoo.comInflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingFebruary 28, 2025 | globenewswire.comInflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor ConferencesFebruary 25, 2025 | globenewswire.comInflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 18, 2025 | globenewswire.comShort Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7%InflaRx (NASDAQ:IFRX - Get Free Report) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 415,200 shares, a drop of 13.7% from the January 15th total of 481,300 shares. Based on an average daily trading volume, of 305,500 shares, the short-interest ratio is presently 1.4 days.February 17, 2025 | marketbeat.comInflaRx Shares Drop After Public Offering PricesFebruary 14, 2025 | marketwatch.comInflaRx dips 16%, prices $30M stock offeringFebruary 14, 2025 | msn.comInflaRx announces ordinary shares and warrants offering, no amount givenFebruary 13, 2025 | markets.businessinsider.comInflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2025 | globenewswire.comInflaRx launches public offering of shares and warrantsFebruary 13, 2025 | msn.comInflaRx Announces Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2025 | globenewswire.comInflaRx (NASDAQ:IFRX) Short Interest UpdateInflaRx (NASDAQ:IFRX - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 248,900 shares, an increase of 15.0% from the December 31st total of 216,500 shares. Based on an average trading volume of 264,900 shares, the days-to-cover ratio is currently 0.9 days.February 1, 2025 | marketbeat.comInflaRx Announces Participation in Guggenheim SMID Cap Biotech ConferenceJanuary 23, 2025 | globenewswire.comShort Interest in InflaRx (NASDAQ:IFRX) Expands By 15.0%InflaRx (NASDAQ:IFRX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 248,900 shares, an increase of 15.0% from the December 15th total of 216,500 shares. Based on an average daily trading volume, of 264,900 shares, the days-to-cover ratio is currently 0.9 days.January 19, 2025 | marketbeat.comInflaRx: Strategic Buy Rating Amidst Regulatory Milestones and Promising PipelineJanuary 18, 2025 | markets.businessinsider.comInflaRx’s Market Potential Bolstered by EU Approval of GohibicJanuary 16, 2025 | markets.businessinsider.comInflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approvalJanuary 16, 2025 | msn.comInflaRx (NASDAQ:IFRX) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of InflaRx in a report on Thursday.January 16, 2025 | marketbeat.comInflaRx announces EC grants marketing authorization to Gohibic for ARDSJanuary 15, 2025 | markets.businessinsider.comInflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDSJanuary 15, 2025 | tipranks.comInflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)January 15, 2025 | globenewswire.comInflaRx Announces Participation in January Events in San FranciscoJanuary 7, 2025 | markets.businessinsider.comShort Interest in InflaRx (NASDAQ:IFRX) Increases By 37.9%InflaRx (NASDAQ:IFRX - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 216,500 shares, an increase of 37.9% from the November 30th total of 157,000 shares. Based on an average daily volume of 243,600 shares, the short-interest ratio is presently 0.9 days.December 30, 2024 | marketbeat.comInflaRx announces first patient dosed in 2a study of CSU, HSDecember 20, 2024 | markets.businessinsider.comInflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory DrugDecember 20, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reissued a "buy" rating and set a $8.00 target price on shares of InflaRx in a report on Friday.December 20, 2024 | marketbeat.comInflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904December 20, 2024 | globenewswire.comInflaRx (NASDAQ:IFRX) Shares Up 3.8% - Still a Buy?InflaRx (NASDAQ:IFRX) Trading Up 3.8% - Time to Buy?December 6, 2024 | marketbeat.comInflaRx initiated with a Buy at Lucid CapitalNovember 20, 2024 | markets.businessinsider.com Remove Ads Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Media Mentions By Week IFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.270.82▲Average Medical News Sentiment IFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼52▲IFRX Articles Average Week Remove Ads Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rapport Therapeutics News Today Solid Biosciences News Today Heron Therapeutics News Today Allogene Therapeutics News Today Arcturus Therapeutics News Today Astria Therapeutics News Today Monte Rosa Therapeutics News Today Cryoport News Today Aura Biosciences News Today Esperion Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IFRX Stock Free IFRX Stock Alerts